Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for ...

Title: The Evolution of Anti-CD20 Treatment for Multiple Sclerosis ... The discussion of these refinements includes improving the extent of B-cell depletion, reducing infusion-related reactions ...